MSLN and neoplasm: This strategy has shown superior efficacy compared to bsAbs directed against the membrane-distal region of MSLN (MSLNMDR) that is often shed into the bloodstream or present in non-tumor tissues, potentially leading to on-target/off-tumor toxicity (NCT06756035, NCT06523803, NCT06255665) (Table 1).